| Autor: |
Di Lorenzo A; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.; Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy., Campogiani L; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.; Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy., Iannetta M; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.; Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy., Iannazzo R; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., Imeneo A; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., Alessio G; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., D'Aquila V; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., Massa B; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., Fato I; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., Rindi LV; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy., Malagnino V; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.; Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy., Teti E; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.; Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy., Andreoni M; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.; Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy., Sarmati L; Department of System Medicine, Tor Vergata University, 00133 Rome, Italy.; Infectious Disease Clinic, Policlinico Tor Vergata, 00133 Rome, Italy. |
| Abstrakt: |
Co-infections during COVID-19 may worsen patients' outcomes. This study reports the results of a screening assessing the presence of co-infections among patients hospitalized for SARS-CoV-2 infection in the Infectious Diseases-Ward of the Policlinico Tor Vergata Hospital, Rome, Italy, from 1 January to 31 December 2021. Data on hepatitis B and C virus, urinary antigens for legionella pneumophila and streptococcus pneumoniae, pharyngeal swab for respiratory viruses, QuantiFERON ® -TB Gold Plus assay (QFT-P), blood cultures and pre-hospitalization antibiotic prescription were recorded. A total of 482 patients were included, 61% males, median age of 65 years (IQR 52-77), median Charlson comorbidity index of 4 (IQR 2-5). The mortality rate was 12.4%; 366 patients needed oxygen supply. In total, 151 patients (31.3%) received home antibiotics without any association with the outcome. No significant association between mortality and the positivity of viral hepatitis markers was found. Out of 442 patients, 125 had an indeterminate QFT-P, associated with increased mortality. SARS-CoV-2 was the only respiratory virus detected among 389 pharyngeal swabs; 15/428 patients were positive for S. pneumoniae ; none for L. pneumophila . In total, 237 blood cultures were drawn within 48 h from hospital admission: 28 were positive and associated with increased mortality. In our cohort, bacterial and viral co-infections in COVID-19 hospitalized patients were rare and not associated with higher mortality. |
